SG Americas Securities LLC bought a new stake in The Chemours Company (NYSE:CC - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 60,734 shares of the specialty chemicals company's stock, valued at approximately $822,000.
A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Chemours by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 15,223,961 shares of the specialty chemicals company's stock worth $257,285,000 after purchasing an additional 94,885 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Chemours by 23.8% during the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after buying an additional 839,849 shares during the period. Millennium Management LLC grew its holdings in shares of Chemours by 44.6% during the fourth quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company's stock worth $42,373,000 after buying an additional 773,537 shares during the last quarter. Norges Bank acquired a new position in Chemours in the 4th quarter valued at about $30,702,000. Finally, Dimensional Fund Advisors LP raised its stake in Chemours by 22.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,779,702 shares of the specialty chemicals company's stock valued at $30,077,000 after acquiring an additional 328,414 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Royal Bank Of Canada lowered their target price on Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Morgan Stanley dropped their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Mizuho set a $15.00 price objective on shares of Chemours in a research report on Tuesday, April 15th. Finally, UBS Group lowered their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Chemours has a consensus rating of "Hold" and an average price target of $17.22.
Get Our Latest Report on Chemours
Insider Activity
In other news, insider Damian Gumpel bought 7,822 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average price of $9.95 per share, with a total value of $77,828.90. Following the purchase, the insider now owns 131,701 shares of the company's stock, valued at $1,310,424.95. This trade represents a 6.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Shane Hostetter bought 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The stock was purchased at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the acquisition, the chief financial officer now owns 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 25,672 shares of company stock worth $251,573 over the last ninety days. 0.47% of the stock is currently owned by insiders.
Chemours Price Performance
CC stock traded down $0.25 on Friday, reaching $10.75. 3,297,769 shares of the company's stock were exchanged, compared to its average volume of 2,274,364. The stock has a fifty day moving average of $11.23 and a 200-day moving average of $14.74. The firm has a market cap of $1.61 billion, a PE ratio of 53.75 and a beta of 1.64. The company has a quick ratio of 0.83, a current ratio of 1.75 and a debt-to-equity ratio of 7.01. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $25.54.
Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 23.82% and a net margin of 0.54%. The business had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. Chemours's quarterly revenue was up .4% on a year-over-year basis. As a group, equities analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Dividend Announcement
The firm also recently declared a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were given a $0.0875 dividend. The ex-dividend date was Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio is presently 175.00%.
About Chemours
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Read More

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report